Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 10/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192800 | 0.82 | AR (0.52) | SLC6A4ARNOS2CYP2D6SLC6A2 | |
| SCHEMBL4193837 | 0.81 | AR (0.58) | AR | |
| SCHEMBL27376804 | 0.80 | AR (0.52) | SLC6A4ARNOS2CYP2D6SLC6A2 | |
| SCHEMBL14619456 | 0.79 | SLC6A4 (0.52) | SLC6A4NOS2IGLV6-57SLC6A9 | |
| SCHEMBL4196414 | 0.78 | AR (0.46) | SLC6A4ARNOS2CYP2D6SLC6A2 | |
| SCHEMBL13577155 | 0.76 | SLC6A4 (0.52) | SLC6A4NOS2IGLV6-57SLC6A9 | |
| SCHEMBL1299930 | 0.76 | IGLV6-57 (0.50) | SLC6A4IGLV6-57SLC6A9 | |
| SCHEMBL4200960 | 0.75 | SLC6A2 (0.49) | SLC6A4ARCYP2D6SLC6A2S1PR3 | |
| SCHEMBL177449 | 0.75 | AR (0.53) | ARMRGPRX4 | |
| SCHEMBL4203972 | 0.74 | AR (0.44) | SLC6A4ARNOS2CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| EP-1915338-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | SLC6A4 957/4885AR 1/4885NOS2 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.